Breath sniffing may reveal early clues to cystic fibrosis drug success

NCT ID NCT05726994

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study explores whether analyzing the chemicals in exhaled breath can detect early changes in children with cystic fibrosis who start taking a medication called Kaftrio. Researchers will collect breath samples from 50 children under 12 before and after they begin treatment, looking for shifts in volatile organic compounds (VOCs) that might signal the drug is working. The goal is to develop a non-invasive way to monitor treatment response without needles or scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
exhaled breath collection
What this could lead to
If successful, this could lead to a simple breath test to monitor how well CFTR modulators are working in young children with cystic fibrosis.
What could go wrong
This is a small pilot study, so results may not apply broadly. The breath profile changes may be too subtle or variable to be clinically useful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Necker - Enfants malades

    Paris, Île-de-France Region, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.